Our Project Portfolio

Therapeutic Area

Mechanism

Current Status

Cancer: Multiple Myeloma

NFkB signaling

• Novel target
• Pre-clinical candidate peptide with anti-proliferative activity in human myeloma cell lines, in vivo human xenografts proof of Concept
• Back-up peptides in PK/PD optimization phases
• Patents filed

Cancer: Solid tumours

Cell cycle phosphatases

• Novel selective reversible inhibitors identified with activity in biochemical and cellular assays

Cancer: ER +ve breast cancer

Novel Kinase in ER signaling pathway

• Novel target validation underway (Giamas et al  Nature Med 17,6, 2011 p715-720)
• Patents filed
• Hit /lead discovery underway

Cancer: Resistant ovarian cancer

More

Cell proliferation

• Hit/lead series identified which restore platinum sensitivity in primary human ovarian cancer cell line

Cancer: Metastatic breast cancer

More

Notch pathway

• Polyclonal and monoclonal antibodies identified which inhibit cancer cell line invasion & proliferation
• IP filing underway

Cancer: Breast cancer

Cell cycle kinase

• Pre-clinical candidate pan-kinase inhibitor with anti-proliferative activity in human xenograft models
• Selective Kinase inhibitor leads with in vitro cellular anti- proliferation activity

COPD/asthma exacerbations

Viral inflammation

• Target validated in vitro which preserves protective immune response
• Screening assay established
• Hit discovery underway

COPD/asthma

Inflammation

• Target validation underway

Renal failure

Inflammation

• Target validation underway

Heart Failure

MAP kinase pathway

• Target validation underway
• Assay developed
• Hit compounds

Malaria

More

Plasmodium specific protein kinase

• Target profile activity in blood and transmission stages of life cycle
• Hit compounds with activity against P.falciparum

Rheumatoid arthritis

TNF pathway

• Orally active lead inhibitors of TNFa pathway which are active in mouse collagen RA model and human rheumatoid synovium